Spatial distribution of G6PD deficiency variants across malaria-endemic regions

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Howes, Rosalind E ^a   Dewi, Mewahyu ^b   Piel, Frédéric B ^a   Monteiro, Wuelton M ^c,d   Battle, Katherine E ^a   Messina, Jane P ^a   Sakuntabhai, Anavaj ^e   Satyagraha, Ari W ^f   Williams, Thomas N ^g,h   Baird, J Kevin ^b,i   Hay, Simon I ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c Tropical Medicine Foundation Dr Heitor Vieira Dourado   (Brazil)

^d UNIVERSIDADE DO ESTADO DO AMAZONAS   (Brazil)

^e INSTITUT PASTEUR   (France)

^f EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^h ST MARY S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

G6PD; Genetic variants; Glucose 6 phosphate dehydrogenase deficiency; Haemolysis; Malaria elimination; Plasmodium vivax; Primaquine; Spatial distribution

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PRIMAQUINE;

ARTICLE; CHINA; EVIDENCE BASED PRACTICE; GENE FREQUENCY; GENE MUTATION; GENETIC DISORDER; GENETIC HETEROGENEITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; MALARIA; MALARIA CONTROL; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

ANTIMALARIALS; GENE FREQUENCY; GENETIC VARIATION; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PRIMAQUINE; RISK ASSESSMENT; SPATIAL ANALYSIS; TOPOGRAPHY, MEDICAL; WORLD HEALTH;

EID: 84888341465     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-418     Document Type: Article

References (94)

1. Enzymatic deficiency in primaquine-sensitive erythrocytes. Carson PE, Flanagan CL, Ickes CE, Alving AS, Science 1956 124 484 485
2. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI, PLoS Med 2012 9 1001339 10.1371/journal.pmed.1001339 23152723
3. A research agenda for malaria eradication: diagnoses and diagnostics. The malERA Consultative Group on Diagnoses and Diagnostics, PLoS Med 2011 8 1000396 21311583
4. Consideration of ethics in primaquine therapy against malaria transmission. Baird JK, Surjadjaja C, Trends Parasitol 2011 27 11 16 10.1016/j.pt.2010.08.005 20846906
5. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Baird JK, Clin Microbiol Rev 2013 26 36 57 10.1128/CMR.00074-12 23297258
6. Reinventing primaquine for endemic malaria. Baird JK, Expet Opin Emerg Drugs 2012 17 439 444 10.1517/14728214.2012.720252
7. The role of anti-malarial drugs in eliminating malaria. White NJ, Malar J 2008 7 Suppl 1 8 10.1186/1475-2875-7-S1-S8 19091042
8. A research agenda for malaria eradication: drugs. The malERA Consultative Group on Drugs, PLoS Med 2011 8 1000402 21311580
9. Determinants of relapse periodicity in Plasmodium vivax malaria. White NJ, Malar J 2011 10 297 10.1186/1475-2875-10-297 21989376
10. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Bousema T, Drakeley C, Clin Microbiol Rev 2011 24 377 410 10.1128/CMR.00051-10 21482730
11. Primaquine to prevent transmission of falciparum malaria. White NJ, Lancet Infect Dis 2012 13 175 181 23182932
12. WHO, Guidelines for the treatment of malaria, second edition Geneva: World Health Organization 2010
13. WHO, Global plan for artemisinin resistance containment (GPARC) Geneva: WHO 2011
14. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. White NJ, Qiao LG, Qi G, Luzzatto L, Malar J 2012 11 418 10.1186/1475-2875-11-418 23237606
15. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, White NJ, White LJ, PLoS One 2012 7 37166 10.1371/journal.pone.0037166 22662135
16. G6PD deficiency as protection against falciparum-malaria: an epidemiologic critique of population and experimental studies. Greene LS, Yearb Phys Anthropol 1993 36 153 178 10.1002/ajpa.1330360609 (Pubitemid 23356564)
17. How malaria has affected the human genome and what human genetics can teach us about malaria. Kwiatkowski DP, Am J Hum Genet 2005 77 171 192 10.1086/432519 16001361 (Pubitemid 41022702)
18. G6PD: population genetics and clinical manifestations. Beutler E, Blood Rev 1996 10 45 52 10.1016/S0268-960X(96)90019-3 8861278 (Pubitemid 26138780)
19. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA, Lancet Infect Dis 2009 9 555 566 10.1016/S1473-3099(09)70177-X 19695492
20. Glucose-6-phosphate dehydrogenase deficiency. Cappellini MD, Fiorelli G, Lancet 2008 371 64 74 10.1016/S0140-6736(08)60073-2 18177777
21. G6PD deficiency: Global distribution, genetic variants and primaquine therapy. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, Adv Parasitol 2013 81 133 201 23384623
22. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, et al. Lancet 2012 380 2197 2223 10.1016/S0140-6736(12)61689-4 23245608
23. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al. Lancet 2012 380 2095 2128 10.1016/S0140-6736(12)61728-0 23245604
24. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q, Clin Infect Dis 2012 55 67 e74 10.1093/cid/cis615 22772803
25. Glucose-6-phosphate dehydrogenase deficiency. Luzzatto L, Nathan and Oski's Hematology of Infancy and Childhood Philadelphia: Saunders, Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, 7 2009
26. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: Review of the old and update of the new mutations.Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E, Blood Cells Mol Dis 2012 48 154 165 10.1016/j.bcmd.2012.01.001 22293322
27. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: genetics. Mason PJ, Vulliamy TJ, Encyclopedia of Life Sciences Chichester: John Wiley & Sons, Ltd 2005
28. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group, Bull World Health Organ 1989 67 601 611 2633878
29. Human glucose-6-phosphate dehydrogenase variants. Yoshida A, Beutler E, Motulsky AG, Bull World Health Organ 1971 45 243 253 5316621
30. Toxicity of primaquine in Negroes. Hockwald RS, Arnold J, Clayman CB, Alving AS, JAMA 1952 149 1568 1570 10.1001/jama.1952.72930340027010c
31. Glucose-6-phosphate dehydrogenase deficiency. Beutler E, N Engl J Med 1991 324 169 174 10.1056/NEJM199101173240306 1984194
32. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. Dern RJ, Beutler E, Alving AS, J Lab Clin Med 1954 44 171 176 13184224
33. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, Bull World Health Organ 1960 22 621 631 13793053
34. Cavalli-Sforza LL, Menozzi P, Piazza A, The History and Geography of Human Genes Princeton, New Jersey: Princeton University Press 1994
35. In vivo lability of glucose-6-phosphate dehydrogenase in Gd§ssup§A-§esup§ and Gd§ssup§Mediterranean§ esup§ deficiency. Piomelli S, Corash LM, Davenport DD, Miraglia J, Amorosi EL, J Clin Invest 1968 47 940 948 10.1172/JCI105786 5641629
36. Favism and hemolytic anemia in glucose-6-phosphate dehydrogenase- deficient subjects in North Sardinia. Meloni T, Forteleoni G, Dore A, Cutillo S, Acta Haematol 1983 70 83 90 10.1159/000206700 6408883 (Pubitemid 13076859)
37. Luisada A, Favism. JAMA 1940 115 632 632
38. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Beutler E, Duparc S, Am J Trop Med Hyg 2007 77 779 789 17978087 (Pubitemid 351844308)
39. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Clyde DF, Bull World Health Organ 1981 59 391 395 6976846 (Pubitemid 11024762)
40. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Rattanapong Y, Supeeranuntha L, Wilairatana P, Brittenham G, Looareesuwan S, Southeast Asian J Trop Med Public Health 2001 32 720 726 12041544 (Pubitemid 33642187)
41. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Myanmar: G6PD Mahidol (487G > A) is the most common variant in the Myanmar population. Matsuoka H, Wang J, Hirai M, Arai M, Yoshida S, Kobayashi T, Jalloh A, Lin K, Kawamoto F, J Hum Genet 2004 49 544 547 10.1007/s10038-004-0187-7 15349799 (Pubitemid 39506537)
42. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, Casademont I, Sura T, Laird NM, Singhasivanon P, Quintana-Murci L, Sakuntabhai A, Science 2009 326 1546 1549 10.1126/science.1178849 20007901
43. The reality of using primaquine. Burgoine KL, Bancone G, Nosten F, Malar J 2010 9 376 10.1186/1475-2875-9-376 21184691
44. Glucose-6-phosphate dehydrogenase variants associated with favism in Thai children. Laosombat V, Sattayasevana B, Chotsampancharoen T, Wongchanchailert M, Int J Hematol 2006 83 139 143 10.1532/IJH97.A20513 16513531 (Pubitemid 44227959)
45. Elimination therapy for the endemic malarias. Baird JK, Curr Infect Dis Rep 2012 14 227 237 10.1007/s11908-012-0250-z 22415581
46. G6PD deficiency: the genotype-phenotype association. Mason PJ, Bautista JM, Gilsanz F, Blood Rev 2007 21 267 283 10.1016/j.blre.2007.05.002 17611006 (Pubitemid 47212602)
47. Mourant AE, Kopec AC, Domaniewska-Sobczak K, The distribution of the human blood groups and other polymorphisms London: Oxford University Press 1976
48. Livingstone FB, Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD variants and ovalocytosis in human populations New York: Oxford University Press 1985
49. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E, Blood Cells Mol Dis 2009 42 267 278 10.1016/j.bcmd.2008.12.005 19233695
50. Distribution of certain polymorphic traits in populations of the Indian peninsula and South Asia. Singh S, Isr J Med Sci 1973 9 1225 1237 4359640
51. A new world malaria map: Plasmodium falciparum endemicity in 2010. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI, Malar J 2011 10 378 10.1186/1475-2875-10-378 22185615
52. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HFL, Price RN, Mueller I, Baird JK, Hay SI, PLoS Negl Trop Dis 2012 6 1814 10.1371/journal. pntd.0001814 22970336
53. A world malaria map: Plasmodium falciparum endemicity in 2007. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, Kabaria CW, Manh BH, Elyazar IR, Brooker S, Smith DL, Moyeed RA, Snow RW, PLoS Med 2009 6 1000048 19323591
54. The global public health significance of Plasmodium vivax. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI, Adv Parasitol 2012 80 1 111 23199486
55. The global distribution and population at risk of malaria: past, present, and future. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW, Lancet Infect Dis 2004 4 327 336 10.1016/S1473-3099(04)01043-6 15172341 (Pubitemid 38692697)
56. The neglected burden of Plasmodium vivax malaria. Mendis K, Sina BJ, Marchesini P, Carter R, Am J Trop Med Hyg 2001 64 97 106 11425182 (Pubitemid 32552576)
57. Plasmodium vivax malaria: is it actually benign? Singh H, Parakh A, Basu S, Rath B, J Infect Pub Health 2011 4 91 95 10.1016/j.jiph.2011.03.002
58. Severe Plasmodium vivax malaria among Sudanese children at New Halfa Hospital, Eastern Sudan. Mahgoub H, Gasim GI, Musa IR, Adam I, Parasit Vectors 2012 5 154 10.1186/1756-3305-5-154 22846165
59. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN, Clin Infect Dis 2011 52 612 620 10.1093/cid/ciq249 21292666
60. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, Boaz L, Lilley K, Krause D, Vallely A, Johnson ML, Gatton ML, Shanks GD, Cheng Q, Malar J 2010 9 254 10.1186/1475-2875-9-254 20822506
61. Rationale for short course primaquine in Africa to interrupt malaria transmission. Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, Von Seidlein L, Drakeley C, On behalf of the Primaquine in Africa Discussion Group, Malar J 2012 11 360 10.1186/1475-2875-11-360 23130957
62. Malaria Policy Advisory Committee Meeting, WHO Evidence Review Group Report: the safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide Geneva: World Health Organization 2012
63. Global Malaria Programme WHO, Updated WHO Policy Recommendation: Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria Geneva: World Health Organization 2012
64. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. Edgcomb JH, Arnold J, Yount EH Jr, Alving AS, Eichelberger L, Jeffery GM, Eyles D, Young MD, J Natl Malar Soc 1950 9 285 292 14804087
65. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Alving AS, Hankey DD, Coatney GR, Jones R Jr, Coker WG, Garrison PL, Donovan WN, Am J Trop Med Hyg 1953 2 970 976 13104805
66. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Coatney GR, Alving AS, Jones R Jr, Hankey DD, Robinson DH, Garrison PL, Coker WG, Donovan WN, Di Lorenzo A, Marx RL, Simmons IH, Am J Trop Med Hyg 1953 2 985 988 13104808
67. The hemolytic effect of primaquine. VIII. The effect of drug administration on parameters of primaquine sensitivity. Flanagan CL, Schrier SL, Carson PE, Alving AS, J Lab Clin Med 1958 51 600 608 13525836
68. The hemolytic effect of primaquine and related compounds: a review. Beutler E, Blood 1959 14 103 139 13618370
69. Procedures used at Stateville Penitentiary for the testing of potential antimalarial agents. Alving AS, Craige B, Pullman TN, Whorton CM, Jones R, Eichelberger L, J Clin Invest 1948 27 2 5 10.1172/JCI101956
70. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T, Antimicrob Agents Chemother 2010 54 1762 1768 10.1128/AAC.01135-09 20194698
71. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Luzzatto L, Lancet 2010 376 739 741 10.1016/S0140-6736(10) 60396-0 20599264
72. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, Luzzatto L, Blood 2012 120 4123 4133 10.1182/blood-2012-03-416032 22993389
73. Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A-). Galiano S, Gaetani GF, Barabino A, Cottafava F, Zeitlin H, Town M, Luzzatto L, BMJ 1990 300 236 (Pubitemid 20045529)
74. Glucose-6-phosphate dehydrogenase deficiency. Mehta AB, Postgrad Med J 1994 70 871 877 10.1136/pgmj.70.830.871 7870632
75. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, Richardson A, Teo YY, Small K, Wilson J, Jallow M, Sisay-Joof F, Pinder M, Sabeti P, Kwiatkowski DP, Rockett KA, Eur J Hum Genet 2009 17 1080 1085 10.1038/ejhg.2009.8 19223928
76. 1000 Genomes-A Deep Catalog of Human Genetic Variation.http://www. 1000genomes.org
77. International HapMap Project. http://hapmap.ncbi.nlm.nih.gov
78. The global distribution of the Duffy blood group. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, Zimmerman PA, Barnadas C, Beall CM, Gebremedhin A, Menard D, Williams TN, Weatherall DJ, Hay SI, Nat Commun 2011 2 266 21468018
79. WHO, World Malaria Report 2012 Geneva: World Health Organization 2012
80. Boyd MF, An Introduction to Malariology Cambridge, MA: Harvard University Press 1930
81. The international limits and population at risk of Plasmodium vivax transmission in 2009. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI, PLoS Negl Trop Dis 2010 4 774 10.1371/journal.pntd.0000774 20689816
82. Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, Owour B, Luckhart S, Wirtz RA, Barnwell JW, Rosenberg R, Am J Trop Med Hyg 2006 75 575 581 17038676 (Pubitemid 46941258)
83. Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. Culleton R, Ndounga M, Zeyrek FY, Coban C, Casimiro PN, Takeo S, Tsuboi T, Yadava A, Carter R, Tanabe K, J Infect Dis 2009 200 1465 1469 10.1086/644510 19803728
84. Plasmodium vivax clinical malaria is commonly observed in duffy-negative malagasy people. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, Thonier V, Carod JF, Domarle O, Colin Y, Bertrand O, Picot J, King CL, Grimberg BT, Mercereau-Puijalon O, Zimmerman PA, Proc Natl Acad Sci USA 2010 107 5967 5971 10.1073/pnas.0912496107 20231434
85. Duffy negative antigen is no longer a barrier to plasmodium vivax-molecular evidences from the African West Coast (Angola and Equatorial Guinea). Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, De Sousa B, Do Rosario VE, Benito A, Berzosa P, Arez AP, PLoS Negl Trop Dis 2011 5 1192 10.1371/journal.pntd.0001192 21713024
86. Vivax malaria in mauritania includes infection of a duffy-negative individual. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem Boukhary A, Hafid JE, Ould Ahmedou Salem MS, Trape JF, Basco LK, Briolant S, Malar J 2011 10 336 10.1186/1475-2875-10-336 22050867
87. Shrinking the malaria map: progress and prospects. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, Sabot O, Rodriguez MH, Abeyasinghe RR, Ghebreyesus TA, Snow RW, Lancet 2010 376 1566 1578 10.1016/S0140-6736(10)61270-6 21035842
88. The changing epidemiology of malaria elimination: new strategies for new challenges. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG, Lancet 2013 382 9895 900 911 10.1016/S0140-6736(13)60310-4 23594387
89. UCSF Global Health Group and Malaria Atlas Project, Atlas of Malaria-Eliminating Countries University of California, San Francisco: The Global Health Group, Global Health Sciences 2011
90. India's invisible malaria burden. Hay SI, Gething PW, Snow RW, Lancet 2010 376 1716 1717 10.1016/S0140-6736(10)61084-7 20970180
91. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, Maslen G, O'Brien J, Djimde A, Doumbo O, Zongo I, Ouedraogo JB, Michon P, Mueller I, Siba P, Nzila A, Borrmann S, Kiara SM, Marsh K, Jiang H, Su XZ, Amaratunga C, Fairhurst R, Socheat D, Nosten F, Imwong M, White NJ, Sanders M, Anastasi E, Alcock D, Drury E, et al. Nature 2012 487 375 379 10.1038/nature11174 22722859
92. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, Puangsa-art S, Thanyavanich N, Maneeboonyang W, Day NP, Singhasivanon P, Malar J 2010 9 308 10.1186/1475-2875-9-308 21040545
93. The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. Myat Phone K, Myint O, Aung N, Aye Lwin H, Southeast Asian J Trop Med Public Health 1994 25 710 713 7667719
94. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, Seila S, Ou F, Jian H, Li G, Malar J 2010 9 57 10.1186/1475-2875-9-57 20175930